Portland, OR, July 03, 2022 (GLOBE NEWSWIRE) — According to the report published by Allied Market Research, the global Ulcerative Colitis Market was estimated at $6.2 billion in 2020 and is expected to hit $10.8 billion by 2030, registering a CAGR of 5.7% from 2021 to 2030. The report provides an in-depth analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive scenario, and varying market trends.
Download Sample PDF at: https://www.alliedmarketresearch.com/request-sample/3965
Rise in R&D activities in the pharmaceutical & medical device industry, increase in demand for drugs required for certain treatments, and surge in adoption of various types of ulcerative colitis drugs drive the growth of the global ulcerative colitis market. Furthermore, surge in number of ulcerative colitis cases and emergence of key players for the development of new drugs in the medical device industry are expected to create lucrative opportunities in the industry.
Covid-19 scenario-
- Patients across the world were forced to either cancel or delay elective surgeries, including elective procedures for IBD (Inflammatory Bowel Disease). This, in turn, impacted the global ulcerative colitis market negatively.
- Also, postponement of procedures for ulcerative colitis treatment gave way to a steep decline in the production of medications for ulcerative colitis disease.
The global ulcerative colitis market is analyzed across…
